Clinical Trial Update: MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pembrolizumab (MK-3475A) with or without Calderasib (MK-1084) in completely resected KRAS G12C-mutant non-small cell lung cancer (sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Calderasib (MK-1084)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING